Compass Pathways Stock Slumps After Positive Late-Stage Trial Results ...

The Science of Tripping Comes to Town

Last week, thousands of scientists, practitioners, entrepreneurs, and members of the curious public converged on Denver for the annual Psychedelic Science conference. Neuroscience lectures by scientists from Stanford University and New York University mixed with discussions about clergy on psilocybin, workshops about the use of ecstasy for couples therapy, booths touting sound healing, and a handful of imaginative costumes. I visited for just on…

Compass gains on followup study to psychedelics-based depression treatment

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results ...

Compass psilocybin therapy shown to be effective in largest-ever study in depression

Compass Pathways said Monday it achieved its primary endpoint in an early Phase 3 readout from the largest-ever study of psilocybin for treatment-resistant depression. Yet its stock price fell 36% before the markets opened, apparently signaling investor disappointment that the effect size wasn’t larger. A single dose of the psychedelic drug led to a mean reduction in a measure of clinical depression (the Montgomery-Åsberg Depression Rating Scale…

Compass’ big psychedelic study doesn’t impress investors

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s version of psilocybin could be as a depression treatment.

Compass’ stock slips despite psilocybin trial hitting target

Compass is running another Phase III trial of its psilocybin candidate, which is due to readout in H2 2026.The post Compass’ stock slips despite psilocybin trial hitting target appeared first on Clinical Trials Arena.